BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27230412)

  • 21. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas.
    Ha SY; Lee J; Kang SY; Do IG; Ahn S; Park JO; Kang WK; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Ignatius Ou SH; Kim KM
    Mod Pathol; 2013 Dec; 26(12):1632-41. PubMed ID: 23807774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
    Van Cutsem E; Bang YJ; Mansoor W; Petty RD; Chao Y; Cunningham D; Ferry DR; Smith NR; Frewer P; Ratnayake J; Stockman PK; Kilgour E; Landers D
    Ann Oncol; 2017 Jun; 28(6):1316-1324. PubMed ID: 29177434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma.
    Jung EJ; Jung EJ; Min SY; Kim MA; Kim WH
    Hum Pathol; 2012 Oct; 43(10):1559-66. PubMed ID: 22440694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.
    Kuboki Y; Schatz CA; Koechert K; Schubert S; Feng J; Wittemer-Rump S; Ziegelbauer K; Krahn T; Nagatsuma AK; Ochiai A
    Gastric Cancer; 2018 May; 21(3):401-412. PubMed ID: 28852882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
    Cha Y; Kim HP; Lim Y; Han SW; Song SH; Kim TY
    Mol Oncol; 2018 Jun; 12(7):993-1003. PubMed ID: 29573334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGFR2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract.
    Albin J; Fahrig L; Siemanowski J; Rehkaemper J; Gebauer F; Zander T; Buettner R; Bruns CJ; Schroeder W; Alakus H; Hieggelke L; Quaas A
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5289-5300. PubMed ID: 36416959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer.
    Kim HS; Lee H; Shin SJ; Beom SH; Jung M; Bae S; Lee EY; Park KH; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Park JC; Shin SK; Lee SK; Lee YC; Koom WS; Lim JS; Chung HC; Noh SH; Rha SY; Kim H; Paik S
    Oncotarget; 2017 Jun; 8(24):38389-38398. PubMed ID: 28418920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma.
    Zhang J; Guo L; Liu X; Li W; Ying J
    Oncotarget; 2017 Feb; 8(6):10264-10273. PubMed ID: 28052014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
    Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
    Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
    Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
    Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.
    Stahl P; Seeschaaf C; Lebok P; Kutup A; Bockhorn M; Izbicki JR; Bokemeyer C; Simon R; Sauter G; Marx AH
    BMC Gastroenterol; 2015 Feb; 15():7. PubMed ID: 25649416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.
    Kim SY; Ahn T; Bang H; Ham JS; Kim J; Kim ST; Jang J; Shim M; Kang SY; Park SH; Min BH; Lee H; Kang WK; Kim KM; Park W; Lee J
    Oncotarget; 2017 Feb; 8(9):15014-15022. PubMed ID: 28122360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between HER2 expression and tumor interstitial angiogenesis in primary gastric cancer and its effect on prognosis.
    Li F; Meng G; Tan B; Chen Z; Ji Q; Wang X; Liu C; Niu S; Li Y; Liu Y
    Pathol Res Pract; 2021 Jan; 217():153280. PubMed ID: 33253925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
    Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
    Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization].
    Raskin GA; Mukhina MS; Kravtsova ED; Tsimafeyeu IV; Tyulandin SA; Belyak NP; Kleshchev MA; Orlova RV
    Arkh Patol; 2023; 85(3):40-45. PubMed ID: 37272439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression.
    Zhu DY; Guo QS; Li YL; Cui B; Guo J; Liu JX; Li P
    World J Gastroenterol; 2014 Dec; 20(48):18306-15. PubMed ID: 25561797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TNK2 gene amplification is a novel predictor of a poor prognosis in patients with gastric cancer.
    Shinmura K; Kiyose S; Nagura K; Igarashi H; Inoue Y; Nakamura S; Maeda M; Baba M; Konno H; Sugimura H
    J Surg Oncol; 2014 Mar; 109(3):189-97. PubMed ID: 24178904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design.
    Catenacci DV; Tesfaye A; Tejani M; Cheung E; Eisenberg P; Scott AJ; Eng C; Hnatyszyn J; Marina N; Powers J; Wainberg Z
    Future Oncol; 2019 Jun; 15(18):2073-2082. PubMed ID: 31094225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.
    Fusco N; Rocco EG; Del Conte C; Pellegrini C; Bulfamante G; Di Nuovo F; Romagnoli S; Bosari S
    Mod Pathol; 2013 Jun; 26(6):816-24. PubMed ID: 23348899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibroblast growth factor receptor 1 gene amplification in gastric adenocarcinoma.
    Schäfer MH; Lingohr P; Sträßer A; Lehnen NC; Braun M; Perner S; Höller T; Kristiansen G; Kalff JC; Gütgemann I
    Hum Pathol; 2015 Oct; 46(10):1488-95. PubMed ID: 26239623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.